Status:
COMPLETED
Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To characterize the burden of disease in GERD patients of prescription therapy'
Eligibility Criteria
Inclusion
- Signed informed consent, 18 years or older, diagnosis of GERD
Exclusion
- Peptic ulcer disease, upper gastrointestinal surgery, malignancy
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT00392002
Start Date
October 1 2005
End Date
May 1 2007
Last Update
January 25 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Mississauga, Ontario, Canada
2
Research Site
Toronto, Ontario, Canada